Kodu・Aktsiate loetelu・Cytokinetics Inc

Cytokinetics Inc

Avatud

SektorTervishoid

77.12 -4.14

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

77.13

Max

79.99

Põhinäitajad
By Trading Economics
Sissetulek	-23M -206M
Müük	1.6M 19M
Aktsiakasum	-1.67
Kasumimarginaal	-1,064.485
Töötajad	673
EBITDA	11M -169M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+36.53% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	2.7B 11B
Eelmine avamishind	81.26
Eelmine sulgemishind	77.12

Uudiste sentiment

By Acuity

50%

162 / 340 Pingereas Healthcare

Cytokinetics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. juuli 2026, 18:46 UTC

Event

News

Social Media

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

29. juuli 2026, 20:41 UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

28. juuli 2026, 19:06 UTC

News

Cytokinetics shares are lower amid investor concerns over CEO Robert I. Blum's recent stock option exercise and sale, reported earlier today.

27. juuli 2026, 19:56 UTC

Social Media

Cytokinetics Inc shares are lower, continuing a recent decline, amid social media discussions of a $103 price target and anticipated Myqorzo earnings in 2026.

24. juuli 2026, 23:46 UTC

Cytokinetics Inc shares are lower in after-market hours, continuing recent weakness after three consecutive daily declines. No specific news was identified for the move.

22. juuli 2026, 23:16 UTC

Cytokinetics Inc shares are lower in after-market hours amid broader market weakness, with no specific news identified to explain the decline.

21. juuli 2026, 18:16 UTC

Cytokinetics Inc is trading higher, with no specific news identified. The stock has gained since Monday amid rising commodity prices, particularly copper and oil.

20. juuli 2026, 19:22 UTC

News

Social Media

Cytokinetics shares are lower amid declines in the Biotechnology sector. Myqorzo revenue expectations exceed consensus, with a long-term projection of $1.67 billion by 2030.

Võrdlus sarnastega

Hinnamuutus

Cytokinetics Inc Prognoos

Hinnasiht

By TipRanks

36.53% tõus

12 kuu keskmine prognoos

Keskmine 109.8 USD 36.53%

Kõrge 146 USD

Madal 83 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Cytokinetics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Cytokinetics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

162 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.